Pilot Study of the Effects of Erythritol on Endothelial Function in Patients With Type 2 Diabetes Mellitus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetes mellitus
- Otherwise healthy
Exclusion Criteria:
- Pregnant
- BMI>35 kg/m2
- Long acting insulin treatment
- Other major illness, drug abuse
- Treatment with an investigational drug within 12 weeks
- Treatment with dietary or vitamin supplements
- Smoking within 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Erythritol-containing beverage
|
Orange flavored beverage containing erythritol
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Brachial artery flow mediated dilation
Time Frame: Change from baseline at 28 days
|
Change from baseline at 28 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brachial artery flow-mediated dilation
Time Frame: Change from baseline at 2 hours
|
Reactive hyperemia, carotid femoral pulse wave velocity, fingertip tonometry.
|
Change from baseline at 2 hours
|
|
Reactive hyperemia
Time Frame: Change from baseline at 2 hours and 28 days
|
Change from baseline at 2 hours and 28 days
|
|
|
Carotid femoral pulse wave velocity
Time Frame: Change from baseline at 28 days
|
Change from baseline at 28 days
|
|
|
Fingertip tonometry
Time Frame: Change from baseline at 2 hours and 28 days
|
Change from baseline at 2 hours and 28 days
|
|
|
Urine F2 isoprostanes
Time Frame: Change from baseline at 28 days
|
Change from baseline at 28 days
|
|
|
C-reactive protein
Time Frame: Change from baseline at 28 days
|
Change from baseline at 28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Joseph A. Vita, MD, Boston University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- H-31447
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.